|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
WHO008055513 |
003 |
DE-627 |
005 |
20230629100646.0 |
007 |
cr uuu---uuuuu |
008 |
211221s2023 xx |||||o 00| ||und c |
035 |
|
|
|a (DE-627)WHO008055513
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)ACTRN12621001535864
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EP-Ivermectin-01
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a und
|
245 |
1 |
0 |
|a Ivermectin to prevent Coronavirus
|b A pilot randomized placebo-controlled double-blind trial of single dose oral Ivermectin for post-exposure prophylaxis of SARS-CoV-2
|
264 |
|
1 |
|c 2023
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 10-11-2021, Last updated: 2023-06-29
|
650 |
|
4 |
|a Medical Condition: COVID-19;SARS-CoV-2; COVID-19 SARS-CoV-2;Respiratory - Other respiratory disorders / diseases;Public Health - Epidemiology;Infection - Other infectious diseases
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 3
|
650 |
|
4 |
|a Recruitment Status: Recruiting
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 21. Juni
|
773 |
1 |
8 |
|g year:2023
|g day:21
|g month:06
|
856 |
4 |
0 |
|u https://anzctr.org.au/ACTRN12621001535864.aspx
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2023
|b 21
|c 06
|